Structural basis for mismatch surveillance by CRISPR–Cas9

1For therapeutic applications of CRISPR–Cas9, off-target DNA cleavage must be minimized–. Although a variety of high-fidelity Cas9 variants with improved mismatch discrimination have been developed,, their enhanced specificity comes at the cost of severely reduced rates of on-target DNA cleavage,. Mismatches induce alternative Cas9 conformations,; however, the structures used to guide rational redesign of such variants were bound to on-target DNA and in inactive conformations,. To understand the molecular mechanisms that govern off-target recognition, here we used kinetic analysis to guide sample preparation for cryo-electron microscopy (cryo-EM) and obtained structural snapshots of Cas9 pre-cleavage activation intermediates in the presence of various guide RNA–DNA target strand (gRNA–TS) mismatches.

2We measured the rates of target strand cleavage by Cas9 in the presence of contiguous triple nucleotide mismatches at different positions along the gRNA–TS duplex (Extended Data Fig. 1a, Extended Data Table 1). Compared to rapid on-target cleavage (around 1.0 s−1) the well-characterized protospacer adjacent motif (PAM)-distal 18–20 MM,,, (three mismatches 18–20 bp distal from the PAM) caused a reduction in rate of around 40-fold. Other mismatches (6–8 MM, 9–11 MM and 15–17 MM) resulted in a greater-than-2,000-fold reduction in cleavage rates, with only 20% of the DNA cleaved after 2 h of incubation (Extended Data Fig. 1b).

3Notably, the 12–14 MM allowed Cas9 activation but with rates around 10-fold slower than those of the 18–20 MM. Although Cas9 cleavage is markedly slower for both 12–14 MM-and 18–20 MM-containing DNA than for on-target DNA, more than 80% of either substrate was cleaved within an hour of incubation with Cas9. This time frame for off-target cleavage poses problems for genome-editing applications, which typically occur on the time scale of days to weeks.

4To understand the structural basis for Cas9 activation of mismatched DNA, we vitrified Cas9 with 12–14 MM DNA after a 5-min reaction, in which only around 10% of DNA was cleaved (Extended Data Table 2). We determined a cryo-EM structure at a global resolutionof 3.6 Å (Fig. 1a, Extended Data Fig. 2, Extended Data Table 3). The target-strand-cleaving HNH endonuclease domain was not observed, indicating conformational heterogeneity before activation,. Of note, the distal end of the gRNA–TS duplex was in a linear conformation relative to the PAM-proximal DNA–DNA duplex—a state that differs from previously determined on-target DNA-bound Cas9 structures that depict a kinked duplex (around 70°),, although this state is reminiscent of early R-loop formation intermediates.

5We then vitrified samples of Cas9 with 12–14 MM DNA after a 1-h incubation in which around 80% of the DNA was cleaved (Fig. 1b). Two distinct conformations were observed: a linear duplex conformation consistent with the 5-min structure of 12–14 MM and the kinked duplex conformation described above (Fig. 1a, c). The Cas9 conformations in the two 12–14 MM structures are identical (Fig. 2), but the PAM-distal gRNA–TS duplex end was shifted by around 30 Å and stably docked with REC3 (Fig. 2c). We propose that the linear duplex conformation corresponds to an early intermediate of Cas9, before HNH rearrangement and docking to cleave the DNA,. This is supported by recent structural analyses of catalytically dead Cas9 in complex with various R-loop formation intermediates, several of which exhibit linear gRNA–TS duplex conformations that are similar to our linear duplex structures.

6Notably, positions 12–14 of the gRNA–TS make no direct contacts with the REC3 domain of Cas9 (Fig. 2). Although positions 9–11 and 15–17 make considerable contacts with REC3, the alignment of the gRNA–TS duplex leaves positions 12–14 without any engagement with this domain (Fig. 2d, e). Because REC3 has a critical role in sensing PAM-distal mismatches, the 12–14 MM is likely to be able to evade mismatch discrimination by REC3 as it is positioned in a blind spot.

7We reasoned that mismatches that prevent the PAM-distal gRNA–TS duplex from docking on REC3 would be unable to assume the kinked conformation, leading to considerably reduced DNA cleavage. To test this hypothesis, we determined a structure of Cas9 with 15–17 MM double-stranded DNA (dsDNA) substrate after 1 h of incubation with the enzyme (Fig. 1b). This mismatch inhibits cleavage by Cas9, but still permits DNA binding as measured by high-throughput profiling. We observed only the linear duplex conformation (Fig. 1a, c). These structures support a model in which a linear duplex conformation precedes the canonical kinked duplex conformation that is required for activation, and mismatches that block formation of the kinked conformation escape DNA cleavage by Cas9.

8We next sought to understand how certain mismatches can evade Cas9 discrimination to allow more efficient Cas9 activation and DNA cleavage relative to other mismatches. We examined Cas9 after incubation with 18–20 MM DNA at the 1-min time point at which around 65% of the DNA was cleaved (Extended Data Fig. 1b), to determine whether this more tolerated mismatch undergoes the same structural transition as that of 12–14 MM DNA. Consistent with the fraction of product formation, we observed a mixed population of particles including the linear (Fig. 1a, c) and the kinked duplex conformation. In the kinked duplex structure, we observed HNH docked at the target site scissile phosphate, indicating the fully active conformation. This arrangement of HNH is entirely consistent with the previously observed active Cas9 conformation,. These results suggest that the population of particles showing a linear conformation represents an early intermediate in the pathway, and that the kinking of the gRNA–TS duplex is linked to HNH docking.

9We observed target strand cleavage between nucleotides 3 and 4 (Fig. 3, Extended Data Fig. 3) and non-target strand (NTS) cleavage at the canonical site three bases upstream from the PAM. We report a direct observation of an RuvC active site with the non-target strand bound in the product state (Fig. 3, Extended Data Fig. 3). R986 is in the ‘down’ conformation, stabilizing the two magnesium ions as predicted by molecular dynamics simulations (Fig. 3), whereas F916 wedges between the −2 and −3 bases through stacking interactions and positions the −3 position within the RuvC active site. These observations are in agreement with previous structural and mutagenesis studies,. Our structure suggests a histidine-mediated catalytic mechanism, consistent with two-metal-ion-dependent catalysis and supported by quantum-classical simulations. Furthermore, our product state reveals that the two Mg2+ ions are around 4.2 Å from each other, in agreement with the product state of the histidine-mediated mechanism (Extended Data Fig. 3).

10The fully active configuration requires marked conformational rearrangements, including an approximately 140° rotation of the HNH domain from the inactive state. Furthermore, our structures reveal the molecular mechanisms that underlie this rearrangement. The L1 and L2 linker domains tether HNH to the rest of Cas9 and are often missing from crystal structures, presumably owing to their intrinsic flexibility. However, in our active structure, we observe high-quality density for both L1 and L2. Notably, the L1 helix docks against the minor groove of the PAM-distal gRNA–TS duplex and forms an extended network of interactions, including multiple water-mediated hydrogen bonds with both strands (Fig. 3). As L1 docks on the minor groove, these interactions are gRNA–TS structure-specific rather than sequence-specific and can only occur when the PAM-distal duplex end is in the kinked conformation. This provides a structural basis for our observation that the kinked duplex conformation is an intermediate that precedes Cas9 activation and DNA cleavage. Comparisons of our model with Cas9 structures in inactive (Electron Microscopy Data Bank (EMDB) code EMD-3276) and active (EMD-0584) conformations confirmed that L1 docking against the gRNA–TS duplex is correlated with HNH rearrangement and Cas9 activation (Extended Data Fig. 4). Furthermore, our observation of L1 and L2 ‘locking’ HNH in an active conformation is supported by the slow rate of dissociation of Cas9 from target DNA after cleavage.

11Residue F916 stabilizes the NTS and is within the L2 linker domain; however, within the inactive Cas9 conformation, L2 is positioned more than 20 Å away from the RuvC active site. L1-facilitated positioning of HNH on the target strand enables relocation of L2, which in turn enables positioning of the NTS within the RuvC active site (Extended Data Fig. 4). This mechanism provides a structural explanation for the observed coupling of target strand and NTS cleavage, in which HNH docking precedes alignment of the NTS at the RuvC site for cleavage,. The HNH and RuvC cleavage reactions appear to occur simultaneously because the alignment is rate-limiting.

12Although previous studies have noted the importance of L1 docking onto the gRNA–TS duplex for HNH repositioning,, our observation that a linear gRNA–TS duplex conformation induced by PAM-distal mismatches precludes L1 docking provides a structural explanation for why certain PAM-distal mismatched substrates are able to bind Cas9, while not triggering rapid DNA cleavage.

13The 18–20 MM contains an unusual duplex conformation at the site of the mismatch. The C:C mismatch at position 18 on the target strand, TS(18), is stabilized by stacking interactions with adjacent Watson–Crick base pairs. However, the gRNA is otherwise distorted with gRNA position 2 (gRNA(2)) flipped out by around 180º so that gRNA(1) then intercalates between TS(19) and TS(20). TS(19) participates in water-mediated hydrogen bonds to Q1027, and TS(20) resumes base-pairing with NTS (Fig. 4, Extended Data Fig. 5).

14This unusual nucleic acid conformation is stabilized by RuvC and appears to facilitate the binding of this mismatch. The residues within RuvC that contact and stabilize this distorted configuration are absent in previous on-target structures,,, (Extended Data Fig. 6), despite the overall similarity between our model and a previously determined active on-target Cas9 (Extended Data Fig. 7). This indicates that these resolved RuvC residues are involved only in mismatch binding and not in on-target activation (Fig. 4). Although this mechanism to accommodate certain mismatches may provide an essential mechanism for bacteria to restrict phage variants, it is counterproductive for the use of Cas9 in gene editing.

15Previous rationally engineered variants ‘hyper-accurate Cas9’ (HypaCas9; N692A, M694A, Q695A and H698A mutations) and ‘high-fidelity Cas9’ (Cas9-HF1; N467A, R661A, Q695A and Q926A mutations) achieve somewhat higher fidelity at the expense of up to 100-fold reduced efficiency of on-target DNA cleavage,,. The mutated residues are mainly located within the REC3 domain and make numerous interactions only with the kinked duplex end. Therefore, by abolishing interactions between REC3 and the PAM-distal duplex, these high-fidelity variants reduce the capacity of Cas9 to stabilize the kinked duplex configuration that is required for the docking of L1, and thereby reduce HNH repositioning and cleavage activity. Our data provide a structural explanation for why these high-fidelity Cas9 variants reduce the activation of Cas9 by off-target substrates, but also reduce on-target Cas9 activity.

16To test the role of this loop for mismatch stabilization, we designed a 7-D mutant (in which all seven of the stabilizing residues in Fig. 4b are mutated to aspartic acid) and tested the effects of this mutant on DNA cleavage. Although this 7-D mutant cleaved on-target DNA at a similar rate to wild-type Streptococcus pyogenes Cas9 (SpCas9) (2 s−1), we observed that cleavage of 18–20 MM DNA was 500-fold slower (0.004 s−1) (Fig. 4e). This indicates that this loop is critical for stabilizing the distorted mismatch-induced PAM-distal duplex conformation, thereby allowing the duplex to adopt the kinked conformation that is prerequisite for Cas9 activation. We refer to our designed high-fidelity variant that retains wild-type on-target cleavage rates as ‘SuperFi-Cas9’.

17Because enzyme specificity is a kinetic phenomenon that is not determined solely by the rates of the chemical reaction, we performed a direct competition assay, in which on-target and off-target (18–20 MM) dsDNA substrates were mixed simultaneously with enzyme and cleavage was monitored over time. Although wild-type Cas9 showed some preference for on-target substrates (a 1.55-fold specificity ratio favouring the on-target over 18–20 MM off-target DNA), SuperFi-Cas9 showed rapid cleavage of on-target DNA and minimal cleavage of 18–20 MM DNA (6.3-fold preference for on-target DNA) (Fig. 4f, g). The ability to discriminate between on- and off-target DNA substrates without compromising DNA cleavage efficiency appears to be unique to SuperFi-Cas9. Although further studies are needed to fully define the kinetic basis for the change in discrimination, our current data constitute a proof of concept and provide a rationale for engineering improved variants of Cas9 using our structure.

18Through kinetics-guided structural determination, we have described a gRNA–TS duplex conformational intermediate that precedes Cas9 activation (Fig. 5). Notably, we observe that the well-characterized and widespread off-target cleavage of DNA containing mismatches at the extreme PAM-distal end (positions 18–20 (refs.,,,,)) is attributed to a unique mechanism that stabilizes a highly distorted duplex conformation, involving a domain loop in RuvC that penetrates the duplex. This region is missing in previously determined structures of Cas9, which suggests that it has a role solely in mismatch tolerance at these positions. Our results provide molecular insights into the underlying structural mechanisms that govern off-target effects of Cas9, and provide a molecular blueprint for the design of next-generation high-fidelity Cas9 variants that reduce off-target DNA cleavage while retaining efficient cleavage of on-target DNA.

19SpCas9 was expressed and purified as described previously.

20DNA duplexes (55 nt) were prepared from PAGE-purified oligonucleotides synthesized by Integrated DNA Technologies. DNA duplexes used in cleavage assays were prepared by mixing 6-FAM- or Cy3-labelled target strands with unlabelled non-target strands at a 1:1.15 molar ratio in annealing buffer (10 mM Tris-HCl pH 8, 50 mM NaCl and 1 mM EDTA), heating to 95 °C for 5 min, then cooling to room temperature over the course of 1 h. The sgRNA was purchased from Synthego and annealed in annealing buffer using the same protocol as for the duplex DNA substrates. The sequences of the synthesized oligonucleotides, including the positions of mismatches, are listed in Extended Data Table 1.

21Cleavage reactions were performed in 1× cleavage buffer (20 mM Tris-Cl, pH 7.5, 100 mM KCl, 5% glycerol and 1 mM DTT) at 37 °C.

22The reaction of Cas9 with on- and off-target DNA was performed by preincubating Cas9.gRNA (28 nM active-site concentration of Cas9, 100 nM gRNA) with 10 nM DNA with a 6-FAM label on the target strand in the absence of Mg2+. The reaction was initiated by adding Mg2+ to 10 mM, then stopped at various times by mixing with 0.3 M EDTA (Extended Data Fig. 1). Products of the reaction were resolved and quantified using an Applied Biosystems DNA sequencer (ABI 3130xl). Data were fit using either a single or a double-exponential equation, as shown below.

23Single exponential equation:in which Y represents the concentration of the cleavage product, A1 represents the amplitude and λ1 represents the observed decay rate (eigenvalue). The half-life was calculated as t1/2 = ln(2)/λ1.

24Double exponential equation:in which Y represents the concentration of the cleavage product, A1 represents the amplitude and λ1 represents the observed rate for the first phase. A2 represents the amplitude and λ2 represents the observed rate for the second phase.

25Enzyme specificity is a kinetic phenomenon that is a function of all steps leading up to and including the first largely irreversible step in the pathway and it is common for mutants to introduce a change in specificity determining steps. Therefore, we designed an assay to monitor relative rates of cleavage for on- and off-target DNA when the enzyme was presented with both substrates simultaneously. The competition assay was performed by mixing a solution of 25 nM (active site concentration) Cas9 and 100 nM sgRNA, in the presence of 10 mM Mg2+, with 50 nM on-target DNA and 50 nM off-target DNA, in which the DNA contained a 5′-6-FAM label or a 5′-Cy3 label on the target or off-target DNA, respectively. Time points were collected by mixing with 0.3 M EDTA and reaction products were resolved and quantified by capillary electrophoresis, as described above. On-target cleavage data were fit to a single exponential function and off-target cleavage data were fit to a double exponential function. Discrimination was calculated as the ratio of the total amplitude of on-target cleavage divided by the amplitude for off-target cleavage to derive the relative specificity constants for the on-target DNA compared to the off-target DNA.

26Cas9 in complex with various mismatched DNA substrates was frozen at different time points, on the basis of kinetic analysis (Extended Data Fig. 1). A non-productive mismatch complex (15–17 MM, 1 h); a slow productive mismatch (12–14) at early (5 min) and late (1 h) time points; and a fast productive mismatch (18–20, 1 min) were chosen. MDCC-Cas9 was used for structure determination to couple structural analysis with ongoing kinetic studies monitoring changes in fluorescence. It has previously been shown that the kinetics of MDCC-Cas9 were indistinguishable from those of wild-type enzyme. The cleavage reaction was triggered by mixing 10 µM DNA duplex preincubated with 10 mM MgCl2 and 8 µM MDCC-labelled Cas9: 8 µM gRNA was preincubated with 10 mM MgCl2, in reaction buffer (19 mM Tris-Cl, pH 7.5, 95 mM KCl, 4.75% glycerol and 5 mM DTT) at a 1:1 ratio. Four microlitres of sample was applied to glow-discharged holey carbon grids (C-flat 2/2, Protochips), blotted for 1 s with a blot force of 4 and rapidly plunged into liquid nitrogen-cooled ethane using an FEI Vitrobot MarkIV. Reactions were quenched through vitrification.

27Data were collected on an FEI Titan Krios cryo-electron microscope equipped with a K3 Summit direct electron detector (Gatan). Images were recorded with SerialEM with a pixel size of 1.1 Å for 12–14 MM datasets, and 0.81 Å for 18–20 MM and 15–17 MM datasets, over a defocus range of −1.5 to −2.5 µm. During collection of the 12–14 MM 5-min time-point dataset, a preferred orientation was observed. To ameliorate this, a second dataset was collected at 30° tilt. Movies were recorded at 13.3 electrons per pixel per s for 6 s (80 frames) to give a total dose of 80 electrons per pixel. CTF correction, motion correction and particle picking were performed in real-time using cryoSPARC Live. Further data processing was performed with cryoSPARC v.3.2.

28Multiple rounds of 3D classification within cryoSPARC yielded reconstructions of six distinct Cas9 complexes at resolutions ranging from 2.7 to 3.6 Å (Extended Data Table 3). To aid the separation of multiple Cas9 conformational states from within the same dataset, 3D variability analysis was performed within CryoSPARC. First and last frames from suitable eigenvector trajectory were then used as references for heterogeneous refinement (that is, reference-based 3D classification), and particles from resulting classes were refined using non-uniform refinement and used for final reconstructions. Active Cas9 (Protein Data Bank (PDB) code: 6O0X) was rigid-body fitted into each map using ChimeraX. Regions of the model not present in a given map were truncated, and flexible fitting was performed using Namdinator. Further modelling was performed using Isolde, and the models were ultimately subjected to real-space refinement as implemented in PHENIX.

29Further information on research design is available in the Nature Research Reporting Summary linked to this paper.

30Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at 10.1038/s41586-022-04470-1.